GELEEN, the Netherlands – Following the successful production of bio-succinic acid under the trademark Biosuccinium® since 2012, Reverdia’s parent companies — Royal DSM and Roquette — have decided on a strategic shift in the continuing operations of their joint venture.
Effective April 1, 2019, the joint venture Reverdia will be dissolved and the partners will transfer the rights and obligations related to Reverdia’s Biosuccinium plant in Cassano, Italy, to Roquette. Under a non-exclusive license from DSM, Roquette will operate the plant and continue serving customers of Biosuccinium. Customer service, order processing, and marketing and sales will be integrated into Roquette’s existing business to ensure a smooth transition. DSM, the original developer of the Biosuccinium technology, will assume the role of exclusive licensor, in line with its business model in this field.
Atul Thakrar, President of Bio-based Products and Services at DSM, said, “The Reverdia joint venture has proven Biosuccinium technology to be the most sustainable and competitive bio-succinic acid on the market today. We have gone well beyond the start-up phase, and the Biosuccinium brand will continue to grow under the leadership of our partner Roquette. This is an example of DSM doing what it does best — establishing market-leading technologies and commercializing them.”
“After the success of the collaboration with DSM through the joint venture, we will integrate the Biosuccinium product line within our global business organization. Our sales force will continue to support our customers’ growth,” said Bruno Plancke, Vice President of the Industry Global Business Unit at Roquette.
DSM, the original developer of the Biosuccinium technology, will become the exclusive licensor to strategic customers and other third parties interested in the integration of the Biosuccinium production process into their value chains. Bio-succinic acid is a platform molecule with applications in a range of large-volume markets. DSM’s technology has matured to a point where the rollout potential is significant enough to warrant a focused effort on licensing.
